image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 16.14
1.38 %
$ 796 M
Market Cap
-39.37
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STAA stock under the worst case scenario is HIDDEN Compared to the current market price of 16.1 USD, STAAR Surgical Company is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STAA stock under the base case scenario is HIDDEN Compared to the current market price of 16.1 USD, STAAR Surgical Company is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STAA stock under the best case scenario is HIDDEN Compared to the current market price of 16.1 USD, STAAR Surgical Company is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STAA

image
$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
314 M REVENUE
-2.64%
-12.6 M OPERATING INCOME
-44.88%
-20.2 M NET INCOME
-94.66%
15.7 M OPERATING CASH FLOW
7.75%
-59.2 M INVESTING CASH FLOW
-79.65%
5.72 M FINANCING CASH FLOW
-22.81%
49 M REVENUE
-44.75%
-27.9 M OPERATING INCOME
-491.20%
-34.2 M NET INCOME
-342.97%
642 K OPERATING CASH FLOW
-83.18%
-19.5 M INVESTING CASH FLOW
44.68%
-110 K FINANCING CASH FLOW
-6.81%
Balance Sheet STAAR Surgical Company
image
Current Assets 368 M
Cash & Short-Term Investments 230 M
Receivables 79.3 M
Other Current Assets 58.2 M
Non-Current Assets 142 M
Long-Term Investments 0
PP&E 122 M
Other Non-Current Assets 19.8 M
45.24 %15.56 %11.42 %23.90 %3.89 %Total Assets$509.5m
Current Liabilities 70.3 M
Accounts Payable 16.7 M
Short-Term Debt 3.94 M
Other Current Liabilities 49.7 M
Non-Current Liabilities 41.9 M
Long-Term Debt 34.8 M
Other Non-Current Liabilities 7.08 M
14.89 %3.51 %44.27 %31.03 %6.31 %Total Liabilities$112.2m
EFFICIENCY
Earnings Waterfall STAAR Surgical Company
image
Revenue 314 M
Cost Of Revenue 74.3 M
Gross Profit 240 M
Operating Expenses 252 M
Operating Income -12.6 M
Other Expenses 7.6 M
Net Income -20.2 M
350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)314m(74m)240m(252m)(13m)(8m)(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
76.32% GROSS MARGIN
76.32%
-4.02% OPERATING MARGIN
-4.02%
-0.01% NET MARGIN
-0.01%
-0.01% ROE
-0.01%
-0.00% ROA
-0.00%
-6.35% ROIC
-6.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis STAAR Surgical Company
image
35m35m30m30m25m25m20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -20.2 M
Depreciation & Amortization 6.89 K
Capital Expenditures -23.4 M
Stock-Based Compensation 27.2 M
Change in Working Capital -5.4 M
Others 5.12 M
Free Cash Flow -7.67 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets STAAR Surgical Company
image
Wall Street analysts predict an average 1-year price target for STAA of $54.7 , with forecasts ranging from a low of $45 to a high of $85 .
STAA Lowest Price Target Wall Street Target
45 USD 179.00%
STAA Average Price Target Wall Street Target
54.7 USD 238.73%
STAA Highest Price Target Wall Street Target
85 USD 426.64%
Price
Max Price Target
Min Price Target
Average Price Target
909080807070606050504040303020201010May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership STAAR Surgical Company
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
27 M USD 1
0-3 MONTHS
2.58 M USD 1
3-6 MONTHS
50 K USD 1
6-9 MONTHS
42.6 USD 1
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
STAAR Surgical Announces Realignment of Leadership Structure LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following changes to right size and realign its leadership structure to better address market needs: Warren Foust, Chief Operating Officer, has been promoted to the newly created role of President and Chief Operating Officer. In this expanded role, Mr. Foust will continue to oversee. businesswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
Did STAAR Surgical Company Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- STAA NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures. accessnewswire.com - 1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 month ago
Insiders Are Loading Up on These 6 Stocks Now Among the most notable insider purchases of the past week or so is an almost $20 million buy in an American semiconductor concern. 247wallst.com - 1 month ago
An Investigation Has Commenced on Behalf of STAAR Surgical Company Shareholders. Contact Levi & Korsinsky to Discuss your STAA Losses. NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures. accessnewswire.com - 1 month ago
8. Profile Summary

STAAR Surgical Company STAA

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 796 M
Dividend Yield 0.00%
Description STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Contact 25651 Atlantic Ocean Drive, Lake Forest, CA, 92630 https://www.staar.com
IPO Date Feb. 24, 1992
Employees 1157
Officers Dr. Magda Michna Ph.D. Chief Development Officer and Chief Clinical, Regulatory & Medical Affairs Officer Ms. Deborah J. Andrews Interim Chief Financial Officer Mr. Stephen C. Farrell CFA Chief Executive Officer & Lead Director Mr. Nathaniel B. Sisitsky Esq. Senior Vice President, General Counsel & Corporate Secretary Ms. Nancy Sabin Chief Marketing Officer Mr. Brian Moore Vice President of Investor Relations & Corporate Development Mr. Thomas G. Frinzi Advisor Mr. Warren Foust President & Chief Operating Officer Mr. James Francese Senior Vice President of Commercial Operations - North America & APAC Dr. Scott D. Barnes M.D. Chief Medical Officer